Hemorrhagic Radiation Cystitis. (June 2015)

• Record Type: Journal Article
• Authors: Mendenhall, William M.; Henderson, Randal H.; Costa, Joseph A.; Hoppe, Bradford S.; Dagan, Roi; Bryant, Curtis M.; Nichols, Romaine C.; Williams, Christopher R.; Harris, Stephanie E.; Mendenhall, Nancy P.
• Is Part Of: American journal of clinical oncology. Volume 38:Number 3(2015)
• Publication Date: 2015-06
• Subjects: Cancer -- Treatment -- Periodicals; Oncology -- Periodicals; Tumors -- Periodicals; 616.994005
• DOI: 10.1097/COC.0000000000000016
• Languages: English
• ISSNs: 0277-3732

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <p>The optimal management of persistent hemorrhagic radiation cystitis is ill-defined. Various options are available and include oral agents (ie, sodium pentosan polysulfate), intravenous drugs (ie, WF10), topical agents (ie, formalin), hyperbaric oxygen, and endoscopic procedures (ie, electrical cautery, argon plasma coagulation, laser coagulation). In general, it is best to manage patients conservatively and intervene only when necessary with the option least likely to exacerbate the cystitis. More aggressive measures should be employed only when more conservative approaches fail. Bladder biopsies should be avoided, unless findings suggest a bladder tumor, because they may precipitate a complication.</p> </sec> </abstract>